New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:00 EDTXOMAXOMA Phase III gevokizumab trial likely to miss endpoint, says Summer Street
Summer Street believes Xoma's Phase III trial for gevokizumab will likely not meet the primary endpoint of being effective in treating eye involvement in patients with BehÁetís disease. The firm says prior clinical trials indicate that the product is only a weak anti-inflammatory agent.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
08:13 EDTXOMACapital Ventures reports 6.3% passive stake in XOMA
Subscribe for More Information
December 9, 2014
09:09 EDTXOMAXOMA raises $40M in a registered direct offering
XOMA (XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. Cowen and Company is acting as the sole placement agent.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use